Patents Examined by Anish Gupta
  • Patent number: 8278280
    Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: October 2, 2012
    Assignee: Amgen Inc.
    Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
  • Patent number: 8268781
    Abstract: In the current invention peptides, which are derived from GLP-1 (glucagon-like peptide-1) and exendin-3 and/or exendin-4, are provided which bond to the GLP-receptor and can be used, labeled or unlabeled, for the production of an agent for diagnostic and therapy of benign and malignant diseases, in which GLP-1 receptor expression plays a role.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: September 18, 2012
    Assignee: Philipps-Universitat Marburg
    Inventors: Martin Gotthardt, Martin Béhé, Thomas Behr, Burkhard J. Göke
  • Patent number: 8269026
    Abstract: The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
    Type: Grant
    Filed: July 3, 2010
    Date of Patent: September 18, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christophe Moinet, Liliane Halab, Nathalie Turcotte, Monica Bubenik, Marc Courchesne, Carl Poisson, Oswy Z. Pereira, Paul Nguyen-Ba, Bingcan Liu, Nathalie Chauret, Caroline Cadilhac, Laval Chan Chun Kong
  • Patent number: 8263562
    Abstract: The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. The composite medicine containing the said peptide, its preparation method, and the polynucleotide for coding the said peptide are also disclosed.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: September 11, 2012
    Inventors: Yun Cheng, Ruihe Yu, Wanzhou Zhao, Jun Zhao, Jing Li
  • Patent number: 8258101
    Abstract: This invention relates to new peptide-based compounds and their use in therapeutically effective treatments as well as for diagnostic imaging techniques. More specifically the invention relates to the use of such peptide-based compounds used as targeting vectors that bind to receptors associated with angiogenesis, in particular the ?v?3 integrin receptor. Such contrast agents may thus be used for diagnosis of for example malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma. Moreover such compounds may also be used in therapeutic treatment of these diseases.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: September 4, 2012
    Assignee: GE Healthcare AS
    Inventor: Alan Cuthbertson
  • Patent number: 8252902
    Abstract: The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: August 28, 2012
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, Christoph Rader, Subhash C. Sinha, Richard A. Lerner
  • Patent number: 8247422
    Abstract: The invention relates to the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in modulating an immune or inflammatory response: wherein: Z=O or S; n=1-3; R3=—CO2R8, —C(O)SR8, —C(O)NHR8, —C(S)OR8, —C(S)SR8, —C(S)NHR8, —C(NH)SR8 or —C(NH)NHR8, wherein R8 is —H or alkyl; R4=—H, —CH2R5 or —CH2CH2R5, wherein R5 independently has one of the meanings of R3; B=—NR2—, —CH2NR2—, —CH2CH2NR2—, —CH2CHR7— or —CH2O—, wherein R2 is H or a C1-3 alkyl, alkenyl or alkynyl group, and R7 is H or a C1-3 alkyl or alkoxy group; A=wherein R1=—NH2 or —OH, C and D are each, independently, a 5- or 6-membered, substituted or unsubstituted, aromatic or non-aromatic ring which may also contain one or more heteroatoms, and C is connected to group B in any available position.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: August 21, 2012
    Inventor: Dan Stoicescu
  • Patent number: 8247533
    Abstract: Disclosed are peptide structures that are stable in aqueous and non-aqueous media where a first linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini is joined by at least one turn region to a second linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini. The peptide chains can be joined at the C terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain, a C terminus of one of the linear peptide chains with a C terminus of the other linear peptide chain, or an N terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: August 21, 2012
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: John L. Kulp, III, Thomas D. Clark
  • Patent number: 8247375
    Abstract: This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: August 21, 2012
    Assignee: Affibody AB
    Inventors: Fredrik Nilsson, Tove Eriksson, Andreas Jonsson, Stefan Ståhl, Mikaela Friedman
  • Patent number: 8247576
    Abstract: The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: August 21, 2012
    Assignees: Astex Therapeutics Limited, Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology Limited
    Inventors: Valerio Berdini, Gordon Saxty, Marinus Leendert Verdonk, Steven John Woodhead, Paul Graham Wyatt, Robert George Boyle, Hannah Fiona Sore, David Winter Walker, Ian Collins, Robert Downham, Robin Arthur Ellis Carr
  • Patent number: 8242082
    Abstract: The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: August 14, 2012
    Assignee: Seikagaku Corporation
    Inventors: Isao Nagaoka, Daiju Okuda, Shin Yomogida, Hiroshi Tamura
  • Patent number: 8236950
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: August 7, 2012
    Assignee: Abbott Laboratories
    Inventors: David A. Betebenner, Clarence J. Maring, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Patent number: 8236835
    Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: August 7, 2012
    Assignees: Novartis AG, Xenon Pharmaceuticals Inc.
    Inventors: Natalie Dales, Zaihui Zhang, Rajender Kamboj, Jianmin Fu, Shaoyi Sun, Natalia Pokrovskaia, Serguei Sviridov
  • Patent number: 8227422
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: July 24, 2012
    Assignee: Glaxosmithkline LLC
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Patent number: 8222215
    Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: July 17, 2012
    Assignee: Provid Pharmaceuticals, Inc.
    Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
  • Patent number: 8222425
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng
  • Patent number: 8222256
    Abstract: The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s).
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: July 17, 2012
    Assignee: Exelixis, Inc.
    Inventor: Wentao Zhang
  • Patent number: 8216995
    Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: July 10, 2012
    Assignee: Allergan, Inc.
    Inventors: Kei Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
  • Patent number: 8217142
    Abstract: The invention relates to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu4)4-Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the ?-carbon.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: July 10, 2012
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Ahmed F. Abdel-Magid, Urs Eggmann, Cynthia Anne Maryanoff, Adrian Thaler, Frank J. Villani
  • Patent number: 8207294
    Abstract: A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: June 26, 2012
    Assignee: SciClone Pharmaceuticals, Inc.
    Inventors: Guido Rasi, Enrico Garaci, Francesco Bistoni, Luigina Romani, Paolo Di Francesco